홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALGS
#3397
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+1.30%
월간 변동
-19.10%
6달 변화
-28.19%
년간 변동율
-28.19%
이전 종가
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
양
2
마켓
주식
헬스케어
ALGS
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
뉴스
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos therapeutics appoints James Hassard as chief commercial officer
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos reports synergistic weight loss effect with THR-β agonist
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Aligos Therapeutics stock reaffirmed Buy at H.C. Wainwright
Tracking Baker Brothers Portfolio – Q2 2025 Update
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study